Located in Delray Beach, Florida, PositiveID Corp. (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems with their focus primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Yesterday, the young company took a major step towards prominence with the announcement they have been granted Company Patent No. 8,053,214 from the U.S. Patent and Trademark Office.
The patent was awarded to PositiveID’s MicroFluidic Systems (“MFS”), which is a subsidiary of PositiveID. MFS has a growing patent portfolio where the targeted applications of which are biological sample collection processing and detection from environmental samples and clinical samples. The patent will allow PositiveID to make a substantial impression within the sector and to take advantage of DHS’ $3 billion “Bio Watch Program.”
Leading the way at PositiveID is William J. Caragol whom serves as the company’s CEO. In reference to this press release, Caragol stated, “This latest U.S. Patent demonstrates the vast array of derivative technology stemming from M-BAND, a system developed under a decade of funding received from DHS exceeding $35 million. We believe M-BAND continues to be well positioned as a proven technology to compete for DHS’ Third Generation BioWatch program, a $3 billion program to identify pathogens in the air as part of an early warning system designed to thwart a potential terrorist attack.”